With 8.78 million shares changed hands, the volume of the stock remained lighter than its average volume of 13.11 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.31 whereas the lowest price it dropped to was $2.2. The 52-week range on IOVA shows that it touched its highest point at $12.51 and its lowest point at $1.64 during that stretch. It currently has a 1-year price target of $10.70. Beta for the stock currently stands at 0.89.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IOVA was up-trending over the past week, with a rise of 9.27%, but this was up by 31.38% over a month. Three-month performance dropped to -37.60% while six-month performance fell -73.92%. The stock lost -74.01% in the past year, while it has lost -69.73% so far this year. A look at the trailing 12-month EPS for IOVA yields -1.23 with Next year EPS estimates of -0.77. For the next quarter, that number is -0.28. This implies an EPS growth rate of 12.10% for this year and 31.29% for next year. EPS is expected to grow by 44.97% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 4.17%.
Float and Shares Shorts:
At present, 333.93 million IOVA shares are outstanding with a float of 271.49 million shares on hand for trading. On 2025-05-30, short shares totaled 86.36 million, which was 2586.0 higher than short shares on 1745971200. In addition to Dr. Frederick G. Vogt Esq., J.D., Ph.D. as the firm’s Interim CEO, President, General Counsel, Corporate Secretary & Director, Mr. Jean-Marc Bellemin M.B.A. serves as its CFO, Principal Accounting Officer & Treasurer.
Institutional Ownership:
Through their ownership of 0.81267 of IOVA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, IOVA reported revenue of $49324000.0 and operating income of -$121221000.0. The EBITDA in the recently reported quarter was -$110156000.0 and diluted EPS was -$0.36.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IOVA since 8 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With IOVA analysts setting a high price target of 25.0 and a low target of 2.0, the average target price over the next 12 months is 10.7. Based on these targets, IOVA could surge 1016.07% to reach the target high and fall by -10.71% to reach the target low. Reaching the average price target will result in a growth of 377.68% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.89478 being high and -$1.38954 being low. For IOVA, this leads to a yearly average estimate of -$1.2948.
